source
- Amgen invests $300 million in Puerto Rico biologics plant as Novartis plans to close German oral drug factoryAmgen announced an additional $300 million investment in Puerto Rico to expand its biologics manufacturing capacity in Juncos, building on earlier commitments. The funding will be used to upgrade…
- Atara and Pierre Fabre's T-cell therapy gets new chance for FDA approval after twice rejectedAtara Biotherapeutics and Pierre Fabre Pharmaceuticals have received notice from the U.S. FDA that it will reconsider a previously rejected T-cell therapy. The therapy, which had been turned down…